Antares Pharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company’s injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Sumatriptan Injection USP for the acute […]
Read MoreOver the last few months, stocks have finally started to fall after one of the longest bull markets in history. While these last couple of months have been painful, this downturn has presented a few incredible buying opportunities for stocks that appear to be woefully under priced. Here’s what you need to know about three […]
Read MoreWe’re heading into earnings season after a particularly difficult fourth quarter that saw the S&P 500 briefly cross into bear market territory on Christmas Eve. Since then, the index has rebounded. However, there’s still quite a bit of ground to make up. In a report from Goldman Sachs, U.S. chief equity strategist David Kostin said […]
Read MoreThe last quarter of 2018 was one we’d all like to forget. And while stocks have been on a quiet tear so far this year, there’s still cause for concern. We’ve already seen negative surprises from Netflix (NASDAQ: NFLX), with its strong subscriber growth but disappointing revenue figures that sent the stock falling today, and […]
Read MoreMany biotech stocks were riding high this summer, but have plunged in the last few months along with much of the rest of the market. But for two drugmakers, this selloff looks overblown. And both could prove to be big winners next year with potential blockbuster drugs hitting the market. Here’s what you need to […]
Read MoreThe market hates biotechs right now, but some in the sector could bounce back in 2019. Both of the following stocks have been beaten down recently with one down -38% year-to-date, and the other down nearly -40% in the last month. However, both have promising drug candidates in their pipelines, and positive news could send […]
Read MoreNektar Therapeutics (NASDAQ: NKTR) has been on a rollercoaster ride. Between March 2017 and March 2018, the stock rose more than 600%. Since then however, it has fallen -65%. The commercial-stage biotech fell -36.5% in October alone as investors lost faith in the stock. So what happened? Earlier this year, Bristol-Myers Squibb (NYSE: BMY) shelled […]
Read MoreYou’ve heard the phrase, “be greedy when others are fearful.” Judging by the plunge in stocks this month, I think it’s safe to say investors are spooked. Market sell-offs like we’ve seen in the last few weeks tend to create opportunities, and there are two good opportunities in the healthcare sector that investors can now […]
Read MorePot stocks have been on a wild tear this year. For one example, look to Canadian marijuana cultivator and distributor Tilray (NASDAQ: TLRY), which went public in June. The stock peaked last week at $300 per share, an astounding 856% jump from IPO prices. And nine days later, the stock sits at $131. Despite this […]
Read More